Investigating the effectiveness of whole-virus, protein-based, and vector-based SARS-CoV-2 vaccines on the rates of COVID-19 infection, hospitalization, and mortality: a historical cohort study in Iran

被引:0
作者
Tanbakuchi, Davoud [1 ]
Razavizadeh, Nadiasadat Taghavi [1 ]
Salari, Maryam [1 ]
Farkhani, Ehsan Mosa [2 ]
Shakeri, Mohammad Taghi [1 ]
Tabatabaee, Seyed Saeed [3 ,4 ]
Raesi, Rasoul [5 ]
Ghavami, Vahid [1 ]
机构
[1] Mashhad Univ Med Sci, Sch Hlth, Dept Biostat, Mashhad, Iran
[2] Mashhad Univ Med Sci, Sch Hlth, Dept Epidemiol, Mashhad, Iran
[3] Mashhad Univ Med Sci, Social Determinants Hlth Res Ctr, Mashhad, Iran
[4] Mashhad Univ Med Sci, Sch Hlth, Dept Management Sci & Hlth Econ, Mashhad, Iran
[5] Torbat Jam Fac Med Sci, Sch Hlth, Dept Publ Hlth, Torbat Jam, Iran
关键词
COVID-19; Vaccine; Infection; Hospitalization; Virus; Whole-virus; Protein; Vector;
D O I
10.1186/s12879-025-10449-w
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
BackgroundEach of the Coronavirus disease 2019 (COVID-19) vaccines has its characteristics that can affect their effectiveness in preventing hospitalization and patient mortality. The present study aimed to determine the effectiveness of COVID-19 vaccines, including whole-virus, protein-based, and vector-based on COVID-19 infection, hospitalization, and mortality.MethodsThe current cohort study was conducted using the data of all people who received at least two doses of each type of COVID-19 vaccine from March 2020 to August 2022 in Khorasan Rzavi province. Quantitative data were characterized using measures of central tendency and dispersion, while the risks of infection, hospitalization, and mortality were assessed for each type of vaccine. Logistic regression was employed to evaluate the effect of various vaccine types on infection rate, hospitalization, and mortality while adjusting for other independent variables.ResultsIn this study, over 2 million vaccinated individuals had received at least two doses of the COVID-19 vaccine. Whole-virus vaccines, which had an infection rate of 3%, a hospitalization rate of 1.4%, and a mortality rate of 0.2%, were the most effective vaccines. The study also identified several factors associated with an increased risk of COVID-19 infection, hospitalization, and mortality, including kidney disease, cardiovascular disease, respiratory issues, age, sex, diabetes, olfactory dysfunction, fever, chills, body mass index (BMI), and the type of vaccine.ConclusionThis study highlights the substantial impact of COVID-19 vaccination in reducing infection, hospitalization, and mortality rates in Iran. The results support the use of whole-virus and vector-based vaccines as more effective options for preventing COVID-19 outcomes. The study also emphasizes the importance of considering various factors, including medical history and side effects, when evaluating the effectiveness of different vaccine types. The findings of this study can inform public health policy and vaccination strategies in Iran and other countries.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Newcastle disease virus vector-based SARS-CoV-2 vaccine candidate AVX/COVID-12 activates T cells and is recognized by antibodies from COVID-19 patients and vaccinated individuals
    Torres-Flores, Alejandro
    Ontiveros-Padilla, Luis Alberto
    Madera-Sandoval, Ruth Lizzeth
    Tepale-Segura, Araceli
    Gajon-Martinez, Julian
    Rivera-Hernandez, Tania
    Ferat-Osorio, Eduardo Antonio
    Cerbulo-Vazquez, Arturo
    Arriaga-Pizano, Lourdes Andrea
    Bonifaz, Laura
    Paz-De la Rosa, Georgina
    Rojas-Martinez, Oscar
    Suarez-Martinez, Alejandro
    Peralta-Sanchez, Gustavo
    Sarfati-Mizrahi, David
    Sun, Weina
    Chagoya-Cortes, Hector Elias
    Palese, Peter
    Krammer, Florian
    Garcia-Sastre, Adolfo
    Lozano-Dubernard, Bernardo
    Lopez-Macias, Constantino
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [42] Risk of SARS-CoV-2 infection, hospitalization, and death for COVID-19 in people with Parkinson disease or parkinsonism over a 15-month period: A cohort study
    Zenesini, Corrado
    Vignatelli, Luca
    Belotti, Laura Maria Beatrice
    Baccari, Flavia
    Calandra-Buonaura, Giovanna
    Cortelli, Pietro
    Descovich, Carlo
    Giannini, Giulia
    Guaraldi, Pietro
    Guarino, Maria
    Loddo, Giuseppe
    Pantieri, Roberta
    Perlangeli, Vincenza
    Scaglione, Cesa
    Stivanello, Elisa
    Trombetti, Susanna
    D'Alessandro, Roberto
    Baldin, Elisa
    Nonino, Francesco
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (11) : 3205 - 3217
  • [43] How Healthy Lifestyle Habits Have Interacted with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccinations: Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study
    Orui, Masatsugu
    Obara, Taku
    Ishikuro, Mami
    Noda, Aoi
    Shinoda, Genki
    Murakami, Keiko
    Nakamura, Tomohiro
    Metoki, Hirohito
    Ogishima, Soichi
    Izumi, Yoko
    Nakaya, Naoki
    Hozawa, Atsushi
    Ishii, Tadashi
    Nagami, Fuji
    Yamamoto, Masayuki
    Kuriyama, Shinichi
    JMA JOURNAL, 2024, 7 (03): : 353 - 363
  • [44] Lethality of SARS-CoV-2 infection-a comparative autopsy study focusing on COVID-19 development and virus variants
    Schwab, Constantin
    Merle, Uta
    Schirmacher, Peter
    Longerich, Thomas
    HISTOPATHOLOGY, 2023, 83 (02) : 242 - 251
  • [45] A novel pseudovirus-based mouse model of SARS-CoV-2 infection to test COVID-19 interventions
    Tseng, Ssu-Hsueh
    Lam, Brandon
    Kung, Yu Jui
    Lin, John
    Liu, Li
    Tsai, Ya Chea
    Ferrall, Louise
    Roden, Richard B. S.
    Wu, T. C.
    Hung, Chien-Fu
    JOURNAL OF BIOMEDICAL SCIENCE, 2021, 28 (01)
  • [46] Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses
    Bos, Rinke
    Rutten, Lucy
    van der Lubbe, Joan E. M.
    Bakkers, Mark J. G.
    Hardenberg, Gijs
    Wegmann, Frank
    Zuijdgeest, David
    de Wilde, Adriaan H.
    Koornneef, Annemart
    Verwilligen, Annemiek
    van Manen, Danielle
    Kwaks, Ted
    Vogels, Ronald
    Dalebout, Tim J.
    Myeni, Sebenzile K.
    Kikkert, Marjolein
    Snijder, Eric J.
    Li, Zhenfeng
    Barouch, Dan H.
    Vellinga, Jort
    Langedijk, Johannes P. M.
    Zahn, Roland C.
    Custers, Jerome
    Schuitemaker, Hanneke
    NPJ VACCINES, 2020, 5 (01)
  • [47] Effectiveness of AstraZeneca vaccine against SARS-CoV-2 (ChAdox1-S) in reducing in-hospital mortality in individuals with COVID-19 and schizophrenia: A retrospective cohort study
    Dyu, Tiffany
    Leung, Char
    Simoes-e-Silva, Ana Cristina
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [48] Rates of Hospitalization and Death due to COVID-19 in US Veterans With SARS-CoV-2 Infection in the XBB-, JN.1-, and KP-Predominant Eras
    Choi, Taeyoung
    Xie, Yan
    Al-Aly, Ziyad
    OPEN FORUM INFECTIOUS DISEASES, 2025, 12 (03):
  • [49] Duration of SARS-CoV-2 viremia and its correlation to mortality and inflammatory parameters in patients hospitalized for COVID-19: a cohort study
    Hagman, Karl
    Hedenstierna, Magnus
    Rudling, Johan
    Gille-Johnson, Patrik
    Hammas, Berit
    Grabbe, Malin
    Jakobsson, Jan
    Dillner, Joakim
    Ursing, Johan
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2022, 102 (03)
  • [50] The severity of respiratory syncytial virus infection in children during the SARS-CoV-2/COVID-19 pandemic: A nationwide study of 11,915 cases in Germany
    Maslowski, Sarah
    Hohenstein, Sven
    Bollmann, Andreas
    Karagiannidis, Christian
    Papan, Cihan
    Thal, Serge C.
    Wirth, Stefan
    Tenenbaum, Tobias
    Aydin, Malik
    INFECTION, 2024, : 561 - 572